Loading stock…

Convatec Group PLC (2CV) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Convatec Group PLC

2CVMarket cap $5.67BPrice $2.8

Country🇬🇧United Kingdom

SectorHealthcare

IndustryHealthcare Equipment

Makes medical devices for chronic conditions—wound care, ostomy, continence, and infusion products used in hospitals worldwide. Its ostomy bags and wound dressings quietly keep millions of patients with life-altering conditions living normal, dignified daily lives.

In Bastion Portfolios?

52W Return-14%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+6%5

Revenue Forecast

Rev CAGR (1y)+5%4

Rev CAGR (3y)+6%5

Rev CAGR (5y)+6%6

Earnings Forecast

EPS Growth Y+1+134%10

EPS Growth Y+2+12%7

EPS Growth Y+3+10%7

Quality

Margins

EBIT Margin16%6

Net Income Margin5%4

Free Cash Flow Margin9%5

Debt

Net Debt/EBITDA2.73

Efficiency

ROE8%4

ROA3%5

Earnings Stability77

GEAR+AVERAGE39

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)146

P/E Ratio (Forward 3y)117

P/BV4.04

EV Multiples

EV/EBITDA Fwd106

EV/EBIT Fwd127

Yield

Free Cash Flow Yield3.8%5

Dividend Yieldna–

Momentum

Short term

1 month return-8%3

3 month return-0%6

YTD return-10%3

Mid term

Price vs 52wHigh86%7

1 year return-10%3

Long term

3 year return+4%3

5 year return+15%4

Risk Shield

Price Risk

Beta0.76

Volatility46%3

Free Cash Flow

Free Cash Flow Margin9%5

Free Cash Flow Yield3.8%5

Quality

ROCE12%7

Earnings Stability77

Net Debt/EBITDA2.73

02Growth

Is it actually growing, and how fast?

2CVConvatec Group

Revenue FY25$2.4B

GROWTH RATING↗

AVERAGE51 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+5%4

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+6%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+134%10

EPS growth, FY27E+12%7

EPS growth, FY28E+10%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 12%/yr vs revenue 6%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 51% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, in line with the market.5/10

Revenue grew 6%/yr over the last 3 years and is set to keep growing around 6%/yr.

Over five years revenue is set to grow 6%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

2CVConvatec Group

Total return Current14.5%

Price return Current−2.3%

MOMENTUM RATING↗

WEAK33 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return-0%6

YTD return-10%3

MID & LONG-TERM▾SCORE

% of 52-week high86%7

1-year return-10%3

3-year return+4%3

5-year return+15%4

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 10% over the past year, now 14% below its 52-week high. That is right in line with the market.

Returns sit at the market level over three months (+0%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+3.8% over three years and +15% over five), behind 60% of the market.

The stock is underperforming over the past month (-8%) and so far this year (-10%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on ConvaTec. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

2CVConvatec Group

Revenue FY25$2.4B

GROWTH RATING↗

AVERAGE51 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+5%4

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+6%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+134%10

EPS growth, FY27E+12%7

EPS growth, FY28E+10%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 12%/yr vs revenue 6%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 51% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, in line with the market.5/10

Revenue grew 6%/yr over the last 3 years and is set to keep growing around 6%/yr.

Over five years revenue is set to grow 6%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

2CVConvatec Group

Total return Current14.5%

Price return Current−2.3%

MOMENTUM RATING↗

WEAK33 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return-0%6

YTD return-10%3

MID & LONG-TERM▾SCORE

% of 52-week high86%7

1-year return-10%3

3-year return+4%3

5-year return+15%4

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 10% over the past year, now 14% below its 52-week high. That is right in line with the market.

Returns sit at the market level over three months (+0%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+3.8% over three years and +15% over five), behind 60% of the market.

The stock is underperforming over the past month (-8%) and so far this year (-10%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on ConvaTec. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community